SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong quarterly results and rapid growth in its AI-compute business are driving attention, alongside Musks ambitious expansion and revenue outlook; traders are debating the bullish growth story against heavy capital spending, cash burn, and valuation concerns. A possible Tesla merger is also being discussed, but no deal has been agreed.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros sharply raised preliminary quarterly revenue outlook and improved gross-margin expectations, attributed to stronger AI-platform demand, sparked a sharp share-price rebound. Traders largely welcomed the update and speculated about a short squeeze and valuation reset, while others questioned whether margins, cash flow and execution can sustain the improvement.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, a reduced advertising outlook, and concerns about slowing revenue growth, driving a sharp selloff. Traders are divided between viewing the drop as a buying opportunity and expecting further weakness amid questions about ad execution, content, and competition.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys record-high breakout ahead of Q3 results is drawing attention, with traders pointing to raised analyst outlooks and expectations for strong Mounjaro and Zepbound demand to support results and guidance. Many celebrate the momentum and healthcare-sector rotation, while some caution that the rally could fade or that optimism is already priced in.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

The FAA certified Boeings long-delayed 737 MAX 10, clearing a regulatory hurdle and opening the way for production and deliveries. Traders welcomed the milestone but largely questioned its muted stock response, arguing that sustained production and delivery growthnot certification alonewill be needed to support cash flow and the turnaround.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

CEO Paul Pragers comments on strong future power demand, project execution and TeraWulfs powered-shell modelrather than owning depreciating chipshave fueled a sharp, high-volume rebound. Bulls see the interview as highlighting the companys differentiation and a possible reversal, while skeptics view the move as a relief bounce amid lingering financing and sector concerns.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanleys upgrade naming Amazon a top pick, alongside optimism about accelerating AWS growth and Trainium adoption, drove a sharp rebound. Many traders welcomed the move and expect further gains, while others question whether the rally can hold ahead of earnings.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results topped expectations, with a raised outlook and record backlog underscoring strong defense and space demand. Traders welcomed the results and stock gain, while some questioned whether buyers would sustain the move after an intraday pullback.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immixs NEXICART-2 update showing an 89% complete-response rate across 45 patients has put its NXC-201 CAR-T therapy for relapsed/refractory AL amyloidosis in focus, with traders also watching the planned 2027 BLA timeline. The community is bullish on the results and added funding, but some investors remain frustrated that the offering and extended timeline overshadowed the data and may weigh on shares.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Barclays downgrade of Dell and peers has fueled a sharp selloff, as traders debate whether AI-server revenue reflects durable demand or higher memory and component prices, with some questioning the pace of enterprise AI adoption. Bears see valuation and margin risks, while dip buyers point to Dells AI-server backlog and ongoing infrastructure demand; broader tech weakness and interest-rate concerns have added pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom...

Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document

Equity

The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.


Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months...

Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial

Truist Financial raised shares of Solid Biosciences to a "strong-buy" rating in a research note on Monday...

Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Solid Biosciences from a "hold" rating to a "sell" rating in a report on Sunday...

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen research firms that are currently covering the stock...

Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month High  - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Hits New 12-Month High - What's Next...

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - Here's Why

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - What's Next...

Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday...

Solid Biosciences (NASDAQ:SLDB) Trading 6.4% Higher - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Shares Up 6.4% - Here's What Happened...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Neutral Sentiment

<ul class="summary-bullets"><li>FDA reviewers said the study failed to meet its pre-specified primary and secondary efficacy endpoints, finding no statistically significant difference between Deramiocel and placebo after 12 months.</li><li>The documents show that reviewers raised concerns over changes made to the statistical analysis plan for Capricor’s Phase 3 Hope-3 trial.</li><li>Capricor said the FDA’s review was based on an unsigned, incomplete, and obsolete internal draft.</li></ul>Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).However, the company responded by stating that the FDA’s review was based on an unsigned, incomplete, and obsolete internal draft.&nbsp;“Our results are governed by the final analysis plan, SAP version 3.0, which was finalized prior to unblinding. It is critical to understand that the post-hoc analyses in the FDA’s briefing materials rely on SAP version 1.1, an unsigned, incomplete internal draft which became obsolete with the addition of cohort B and did not include content specifically requested by FDA,” said CEO Linda Marbán.&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> also recorded its biggest ever single-day slide. It is currently at its lowest levels since December 2025.<h2 class="st-heading-2">Reviewers Say Deramiocel Study Fails to Meet Primary, Secondary Efficacy Endpoints</h2>The FDA on Monday&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated">released</a> briefing documents ahead of a July 29 meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee. In the documents, FDA reviewers said the study failed to meet its pre-specified primary and secondary efficacy endpoints, finding no statistically significant difference between Deramiocel and placebo after 12 months.Duchenne muscular dystrophy is a rare inherited disorder that mainly affects boys, causing progressive muscle weakness, and there are no FDA-approved treatments specifically for the heart disease that often develops as the condition worsens.The advisory committee will review Capricor’s Biologics License Application (BLA) for the drug before the FDA makes its final decision by the Prescription Drug User Fee Act (PDUFA) target date of Aug. 22, 2026. A PDUFA date is the deadline by which the FDA decides whether to approve a drug for marketing in the United States.<h2 class="st-heading-2">Reviewers Question Changes To Trial Analysis</h2>The documents show that reviewers raised concerns over changes made to the statistical analysis plan (SAP) for Capricor’s Phase 3 Hope-3 trial. In December 2025, Capricor stated that its Phase 3 Hope-3 trial met its primary endpoint of improving upper-limb function and its key secondary endpoint of preserving heart function, with both showing statistically significant results.However, the reviewers said multiple changes were made after the randomized portion of the study, including revisions to the primary and secondary endpoints, analytical methods, and data imputation strategy. They also noted that the final SAP was not submitted for review before the company’s BLA and that the study’s pre-specified procedures for making such changes were not followed.&nbsp;The documents also highlighted a higher rate of hypersensitivity reactions in patients treated with Deramiocel, which it said may have increased the risk of functional unblinding during the trial.<h2 class="st-heading-2">What’s Next?</h2>The advisory committee has been recommended to discuss whether data from the Hope-3 and Hope-2 studies show that Deramiocel can slow the decline in heart function in patients with Duchenne muscular dystrophy.The panel will also consider whether the combined results provide enough evidence that the therapy improves upper-limb function and is an effective treatment for the disease.<h2 class="st-heading-2">Retail’s Take On CAPR</h2>Despite the slump, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid a 320% jump in message volumes. CAPR was also among the top trending stocks on the platform at the time of writing.One user said there’s a “60% chance that they will have to redo the Adequate and controlled cardiac primary trial.”<stembedurl>https://stocktwits.com/PB09/message/660074196</stembedurl>However, another user was confident that Capricor will be able to answer whatever questions the committee will have with “proven data and results.”<stembedurl>https://stocktwits.com/Stormfury66/message/660074439</stembedurl>The stock has shed more than 77% so far this year.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fbrx-stock-surges-why-argenx-buying-forte-biosciences/cZZxWT5R7Cr">FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat car

Capricor Therapeutics Inc

Sarepta Therapeutics Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.40
Prev Close	$5.92
Open	$5.93
Dividend Yield	0.00%
50-Day Moving Average	$8.29
Beta	2.06
Avg. Volume	1.3M
PE Ratio	-3.35

52-Week High	$11.45
52-Week Low	$3.79
Market Capitalization	$634.77M
EPS (Annual)	-$1.99
Price to Book	1.80
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLDB Fundamentals